PD-1 blockage extended the spectrum of clinical activity by immunotherapy beyond immunogenic tumor types, such as melanoma and renal-cell cancer, to treatment-refractory, metastatic non-small-cell lung cancer that is commonly not considered as being responsive to immunotherapy. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.